Redirecting to https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-the-Treatment-of-Patients-with-Recurrent-or-Metastatic-Cutaneous-Squamous-Cell-Carcinoma-cSCC-that-is-Not-Curable-by-Surgery-or-Radiation/default.aspx...

Click here if your browser doesn't automatically take you to this page.